Evidence map›Paper›PMID 32223381›Full record

ArticleHypertension (Dallas, Tex. : 1979)2020

Initial Estimated Glomerular Filtration Rate Decline and Long-Term Renal Function During Intensive Antihypertensive Therapy: A Post Hoc Analysis of the SPRINT and ACCORD-BP Randomized Controlled Trials.

Didier Collard, Tom F Brouwer, Rik H G Olde Engberink, Aeilko H Zwinderman, Liffert Vogt, Bert-Jan H van den Born

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Effects and Mechanisms of Dapagliflozin Treatment on Ambulatory Blood Pressure in Diabetic Patients with Hypertension.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Trial
  8. Article
  9. Baxdrostat and the future of aldosterone-targeted therapy.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Acute Declines in Estimated GFR in Blood Pressure Target Trials and Risk of Adverse Outcomes.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2023
    Observational
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Didier CollardFrom the Department of Vascular Medicine (D.C., B.-J.H.v.d.B.), Amsterdam UMC, University of Amsterdam, The Netherlands.
Tom F BrouwerDepartment of Clinical and Experimental Cardiology (T.F.B.), Amsterdam UMC, University of Amsterdam, The Netherlands.
Rik H G Olde EngberinkDepartment of Nephrology (R.H.G.O.E., L.V.), Amsterdam UMC, University of Amsterdam, The Netherlands.
Aeilko H ZwindermanDepartment of Clinical Epidemiology, Biostatistics and Bioinformatics (A.E.Z.), Amsterdam UMC, University of Amsterdam, The Netherlands.
Liffert VogtDepartment of Nephrology (R.H.G.O.E., L.V.), Amsterdam UMC, University of Amsterdam, The Netherlands.
Bert-Jan H van den BornFrom the Department of Vascular Medicine (D.C., B.-J.H.v.d.B.), Amsterdam UMC, University of Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lowering blood pressure (BP) can lead to an initial decline in estimated glomerular filtration rate (eGFR). However, there is debate how much eGFR decline is acceptable. We performed a post hoc analysis of ACCORD-BP (Action to Control Cardiovascular Risk in Diabetes-Blood Pressure) and SPRINT (Systolic Blood Pressure Intervention Trial), which randomized patients to intensive or standard systolic BP-targets. We determined the relation between initial decline in mean arterial pressure and eGFR. Subsequently, we stratified patients to BP-target and initial eGFR decrease and assessed the relation with annual eGFR decline after 1 year. A total of 13 266 patients with 41 126 eGFR measurements were analyzed. Up to 10 mm Hg of BP-lowering, eGFR did not change. Hereafter, there was a linear decrease of 3.4% eGFR (95% CI, 2.9%-3.9%) per 10 mm Hg mean arterial pressure decrease. The observed eGFR decline based on 95% of the subjects varied from 26% after 0 mm Hg to 46% with a 40 mm Hg mean arterial pressure decrease. There was no difference in eGFR slope (

Indexed as

Glomerular Filtration RateAgedAlbuminuriaAntihypertensive AgentsBlood PressureCardiovascular DiseasesCreatinineDiabetes Mellitus, Type 2FemaleHumansKidneyMaleMiddle AgedRandomized Controlled Trials as TopicRisk FactorsAntihypertensive AgentsCreatininechronic kidney diseasediabetes mellitushypertensionhypertension, renovascularkidney

Identifiers

PMID32223381
PMCPMC7176351

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.